长新冠综合征临床诊治专家共识

doi:10.19871/j.cnki.xfcrbzz.2024.01.016

摘要/Abstract

摘要： 目前,我国进入新型冠状病毒感染（corona virus disease 2019,COVID-19）“乙类乙管”常态化防控阶段,但与COVID-19相关的“长新冠”可以出现全身多系统症状并给患者带来较长期的影响,给全球公共卫生带来了新的挑战。目前国内针对长新冠综合征的诊治、随访及多学科管理尚缺乏相应的共识,相关诊疗工作的开展主要依靠各学科及各中心的经验。本共识基于国内外长新冠综合征的临床与基础研究数据,以及循证医学证据,从长新冠综合征的流行病学、定义、各系统临床表现、辅助检查、诊断、治疗、随访及管理策略等方面进行阐述,提炼出16条共识建议,为指导临床正确地评估与管理长新冠综合征提供理论依据和实践参考。

关键词: 新型冠状病毒感染, 长新冠综合征, 诊治, 专家共识

Abstract: At present, our country has entered the routine control stage of the COVID-19 epidemic. However, “long COVID” associated with COVID-19 may present with multi-system symptoms, leading to enduring effects and introducing new challenges to global public health. In China, consensus is lacking on the diagnosis, treatment, follow-up, and multidisciplinary management of long COVID syndrome. Progress in related diagnostic and therapeutic efforts primarily relies on the collective experiences of various disciplines and hospitals. This consensus is rooted in clinical and foundational research data on long COVID syndrome gathered from both domestic and international sources, supplemented by evidence from evidence-based medicine. It comprehensively addresses aspects such as epidemiology, definition, clinical manifestations in various systems, examinations, diagnosis, treatment, follow-up, and management strategies of long COVID syndrome. We distill 16 recommendations and hope to provide theoretical foundations and practical references to guide the accurate assessment and management of long COVID syndrome in clinical practice.

Key words: Corona virus disease 2019, Long COVID syndrome, Treatment, Expert consensus

中图分类号:

R511
R44

深圳市第三人民医院, 国家感染性疾病临床医学研究中心, 深圳市感染性疾病质量控制中心. 长新冠综合征临床诊治专家共识[J]. 新发传染病电子杂志, 2024, 9(1): 80-87.

Shenzhen Third People's Hospital, National Clinical Research Center for Infectious Diseases, Shenzhen Infectious Disease Quality Control Center. Expert consensus on clinical diagnosis and treatment of long COVID syndrome[J]. Electronic Journal of Emerging Infectious Diseases, 2024, 9(1): 80-87.

参考文献

[1] PERLIS RH, SANTILLANA M, OGNYANOVA K, et al.Prevalence and correlates of long COVID symptoms among us adults[J]. JAMA Netw Open, 2022, 5(10): e2238804.
[2] KREIER F. Long-COVID symptoms less likely in vaccinated people, israeli data say[J]. Nature, 2022. Epub ahead of print.
[3] BALLERING AV, VAN ZON SKR, OLDE HARTMAN TC, et al.Persistence of somatic symptoms after COVID-19 in the netherlands: An observational cohort study[J]. Lancet, 2022, 400(10350):452-461.
[4] CEBAN F, LING S, LUI LMW, et al.Fatigue and cognitive impairment in post-COVID-19 syndrome: A systematic review and meta-analysis[J]. Brain Behav Immun, 2022, 101:93-135.
[5] BULL-OTTERSON L.Post-COVID conditions among adult COVID-19 survivors aged 18-64 and ≥65 years — united states, march 2020-november 2021[EB/OL]. MMWR Morb Mortal Wkly Rep 71, 713 (2022).
[6] AL-ALY Z, BOWE B, XIE Y.Long COVID after breakthrough sars-cov-2 infection[J]. Nat Med, 2022, 28(7):1461-1467.
[7] AYOUBKHANI D, BOSWORTH ML, KING S, et al. Risk of long COVID in people infected with severe acute respiratory syndrome coronavirus 2 after 2 doses of a coronavirus disease2019 vaccine: Community-based, matched cohort study[J]. Open Forum Infect Dis, 2022, 9(9): ofac464.
[8] PHILLIPS B BC, SACKETT D, ET AL. Oxford centre for evidence-based medicine: levels of evidence (march2009). ocebm, 2009[EB/OL]. [2009-06-11]. https://WWW.CEBM.NET/2009/06/OXFORD-CENTRE-EVIDENCE-BASED-MEDICINE-LEVELS-EVIDENCE-MARCH-2009/.
[9] NABAVI N.Long COVID: How to define it and how to manage it[J]. BMJ, 2020, 370:m3489.
[10] WORLD HEALTH ORGANIZATION. A clinical case definition of post COVID-19 condition by a Delphi consensus, 6 October2021. World Health Organization[EB/OL]. https://iris.who.int/handle/10665/345824. Licence: CC BY-NC-SA 3.0 IGO.
[11] CENTERS FOR DISEASE CONTROL AND PREVENTION. Long COVID or Post-COVID Conditions [EB/OL].[2023-07-20]. https://www.cdc.gov/coronavirus/2019-ncov/long-term-effects/index.html.
[12] YELIN D, MOSCHOPOULOS CD, MARGALIT I, et al.Escmid rapid guidelines for assessment and management of long COVID[J]. Clin Microbiol Infect, 2022, 28(7):955-972.
[13] VENKATESAN P.Nice guideline on long COVID[J]. Lancet Respir Med, 2021, 9(2):129.
[14] HUANG L, YAO Q, GU X, et al.1-year outcomes in hospital survivors with COVID-19: A longitudinal cohort study[J]. Lancet, 2021, 398(10302):747-758.
[15] JACKSON CB, FARZAN M, CHEN B, et al.Mechanisms of sars-cov-2 entry into cells[J]. Nat Rev Mol Cell Biol, 2022, 23(1):3-20.
[16] ASAKAWA T, CAI Q, SHEN J, et al.Sequelae of long COVID, known and unknown: A review of updated information[J]. Biosci Trends, 2023, 17(2):85-116.
[17] TANNI SE, FABRO AT, DE ALBUQUERQUE A, et al.Pulmonary fibrosis secondary to COVID-19: A narrative review[J]. Expert Rev Respir Med, 2021, 15(6):791-803.
[18] OJO AS, BALOGUN SA, WILLIAMS OT, et al.Pulmonary fibrosis in COVID-19 survivors: Predictive factors and risk reduction strategies[J]. Pulm Med, 2020, 2020:6175964.
[19] KLIGERMAN SJ, FRANKS TJ, GALVIN JR.From the radiologic pathology archives: Organization and fibrosis as a response to lung injury in diffuse alveolar damage, organizing pneumonia, and acute fibrinous and organizing pneumonia[J]. Radiographics, 2013, 33(7):1951-1975.
[20] HANTASH BM, ZHAO L, KNOWLES JA, et al.Adult and fetal wound healing[J]. Front Biosci, 2008, 13:51-61.
[21] CARSANA L, SONZOGNI A, NASR A, et al.Pulmonary post-mortem findings in a series of COVID-19 cases from northern italy: A two-centre descriptive study[J]. Lancet Infect Dis, 2020, 20(10):1135-1140.
[22] DANI M, DIRKSEN A, TARABORRELLI P, et al.Autonomic dysfunction in‘long COVID': Rationale, physiology, and management strategies[J]. Clin Med (Lond), 2021, 21(1): e63-e67.
[23] MEINHARDT J, RADKE J, DITTMAYER C, et al.Olfactory transmucosal sars-cov-2 invasion as a port of central nervous system entry in individuals with COVID-19[J]. Nat Neurosci, 2021, 24(2):168-175.
[24] STEIN SR, RAMELLI SC, GRAZIOLI A, et al.Sars-cov-2 infection and persistence in the human body and brain at autopsy[J]. Nature, 2022, 612(7941):758-763.
[25] SONG E, ZHANG C, ISRAELOW B, et al.Neuroinvasion of sars-cov-2 in human and mouse brain[J]. J Exp Med, 2021, 218(3): e20202135.
[26] QIN Y, WU J, CHEN T, et al.Long-term microstructure and cerebral blood flow changes in patients recovered from COVID-19 without neurological manifestations[J]. J Clin Invest, 2021, 131(8): e147329.
[27] RAMAN B, BLUEMKE DA, LUSCHER TF, et al.Long COVID: Post-acute sequelae of COVID-19 with a cardiovascular focus[J]. Eur Heart J, 2022, 43(11):1157-1172.
[28] BLITSHTEYN S, WHITELAW S.Postural orthostatic tachycardia syndrome (pots) and other autonomic disorders after COVID-19 infection: A case series of 20 patients[J]. Immunol Res, 2021, 69(2):205-211.
[29] REINDL-SCHWAIGHOFER R, HÖDLMOSER S, DOMENIG O, et al. The systemic renin-angiotensin system in COVID-19[J]. Sci Rep, 2022, 12(1):20117.
[30] OSTERGAARD L.Sars cov-2 related microvascular damage and symptoms during and after COVID-19: Consequences of capillary transit-time changes, tissue hypoxia and inflammation[J]. Physiol Rep, 2021, 9(3): e14726.
[31] PALUDAN SR, MOGENSEN TH. Innate immunological pathways in COVID-19 pathogenesis[J]. Sci Immunol, 2022, 7(67): eabm5505.
[32] DAVITT E, DAVITT C, MAZER MB, et al.COVID-19 disease and immune dysregulation[J]. Best Pract Res Clin Haematol, 2022, 35(3):101401.
[33] GALEOTTI C, BAYRY J.Autoimmune and inflammatory diseases following COVID-19[J]. Nat Rev Rheumatol, 2020, 16(8):413-414.
[34] KLEIN J, WOOD J, JAYCOX J, et al.Distinguishing features of long COVID identified through immune profiling[J]. Nature, 2023, 623(7985):139-148.
[35] KANDUC D.From anti-sars-cov-2 immune responses to COVID-19 via molecular mimicry[J]. Antibodies (Basel), 2020, 9(3): 33.
[36] 廖康生,卢洪洲. 新型冠状病毒奥密克戎变异株的研究进展:对其科学防控措施的启示[J/CD]. 新发传染病电子杂志, 2022, 7(1):1-5.
[37] AL-ALY Z, XIE Y, BOWE B.High-dimensional characterization of post-acute sequelae of COVID-19[J]. Nature, 2021, 594(7862):259-264.
[38] 深圳市第三人民医院,国家感染性疾病临床医学研究中心,深圳市感染性疾病质量控制中心. 深圳市成人新型冠状病毒奥密克戎变异株感染重症临床救治专家共识[J/CD]. 新发传染病电子杂志, 2023, 8(1):93-101.
[39] XIE Y, AL-ALY Z.Risks and burdens of incident diabetes in long COVID: A cohort study[J]. Lancet Diabetes Endocrinol, 2022, 10(5):311-321.
[40] XIE Y, XU E, AL-ALY Z.Risks of mental health outcomes in people with COVID-19: Cohort study[J]. BMJ, 2022, 376: e068993.
[41] XU E, XIE Y, AL-ALY Z.Long-term neurologic outcomes of COVID-19[J]. Nat Med, 2022, 28(11):2406-2415.
[42] NALBANDIAN A, SEHGAL K, GUPTA A, et al.Post-acute COVID-19 syndrome[J]. Nat Med, 2021, 27(4):601-615.
[43] NUNEZ I, GILLARD J, FRAGOSO-SAAVEDRA S, et al.Longitudinal clinical phenotyping of post COVID condition in mexican adults recovering from severe COVID-19: A prospective cohort study[J]. Front Med (Lausanne), 2023, 10:1236702.
[44] NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. COVID-19 rapid guideline: Managing the long-term effects of COVID-19[EB/OL].[2021-12-08]. https://pubmed.ncbi.nlm.nih.gov/33555768/.
[45] D'CRUZ RF, WALLER MD, PERRIN F, et al. Chest radiography is a poor predictor of respiratory symptoms and functional impairment in survivors of severe COVID-19 pneumonia[J]. ERJ Open Res, 2021, 7(1): 00655-2020.
[46] MANDAL S, BARNETT J, BRILL SE, et al.'Long-COVID': A cross-sectional study of persisting symptoms, biomarker and imaging abnormalities following hospitalisation for COVID-19[J]. Thorax, 2021, 76(4):396-398.
[47] CHOPRA V, FLANDERS SA, O'MALLEY M, et al. Sixty-day outcomes among patients hospitalized with COVID-19[J]. Ann Intern Med, 2021, 174(4):576-578.
[48] HUANG C, HUANG L, WANG Y, et al.6-month consequences of COVID-19 in patients discharged from hospital: A cohort study[J]. Lancet, 2023, 401(10393): e21-e33.
[49] BELLAN M, SODDU D, BALBO PE, et al.Respiratory and psychophysical sequelae among patients with COVID-19 four months after hospital discharge[J]. JAMA Netw Open, 2021, 4(1): e2036142.
[50] FABBRI L, MOSS S, KHAN FA, et al.Parenchymal lung abnormalities following hospitalisation for COVID-19 and viral pneumonitis: A systematic review and meta-analysis[J]. Thorax, 2023, 78(2):191-201.
[51] LEE JH, YIM JJ, PARK J.Pulmonary function and chest computed tomography abnormalities 6-12 months after recovery from COVID-19: A systematic review and meta-analysis[J]. Respir Res, 2022, 23(1):233.
[52] WU X, LIU X, ZHOU Y, et al.3-month, 6-month, 9-month, and 12-month respiratory outcomes in patients following COVID-19-related hospitalisation: A prospective study[J]. Lancet Respir Med, 2021, 9(7):747-754.
[53] JOHNSTON J, DORRIAN D, LINDEN D, et al.Pulmonary sequelae of COVID-19: Focus on interstitial lung disease[J]. Cells, 2023, 12(18):2238.
[54] BESUTTI G, MONELLI F, SCHIRO S, et al.Follow-up ct patterns of residual lung abnormalities in severe COVID-19 pneumonia survivors: A multicenter retrospective study[J]. Tomography, 2022, 8(3):1184-1195.
[55] LI X, SHEN C, WANG L, et al.Pulmonary fibrosis and its related factors in discharged patients with new corona virus pneumonia: A cohort study[J]. Respir Res, 2021, 22(1):203.
[56] BOCCHINO M, LIETO R, ROMANO F, et al.Chest ct-based assessment of 1-year outcomes after moderate COVID-19 pneumonia[J]. Radiology, 2022, 305(2):479-485.
[57] LERUM TV, MELTZER C, RODRIGUEZ JR, et al.A prospective study of pulmonary outcomes and chest computed tomography in the first year after COVID-19[J]. ERJ Open Res, 2023, 9(2): 00575-2022.
[58] XIE Y, XU E, BOWE B, et al.Long-term cardiovascular outcomes of COVID-19[J]. Nat Med, 2022, 28(3):583-590.
[59] PUNTMANN VO, CARERJ ML, WIETERS I, et al.Outcomes of cardiovascular magnetic resonance imaging in patients recently recovered from coronavirus disease 2019 (COVID-19)[J]. JAMA Cardiol, 2020, 5(11):1265-1273.
[60] LALA A, JOHNSON KW, JANUZZI JL, et al.Prevalence and impact of myocardial injury in patients hospitalized with COVID-19 infection[J]. J Am Coll Cardiol, 2020, 76(5):533-546.
[61] AMMIRATI E, VARRENTI M, VERONESE G, et al.Prevalence and outcome of patients with acute myocarditis and positive viral search on nasopharyngeal swab[J]. Eur J Heart Fail, 2021, 23(7):1242-1245.
[62] TSCHOPE C, AMMIRATI E, BOZKURT B, et al.Myocarditis and inflammatory cardiomyopathy: Current evidence and future directions[J]. Nat Rev Cardiol, 2021, 18(3):169-193.
[63] ELLIOTT J, WHITAKER M, BODINIER B, et al.Predictive symptoms for COVID-19 in the community: React-1 study of over 1 million people[J]. PLoS Med, 2021, 18(9):e1003777.
[64] GLUCKMAN TJ, BHAVE NM, ALLEN LA, et al.2022 acc expert consensus decision pathway on cardiovascular sequelae of COVID-19 in adults: Myocarditis and other myocardial involvement, post-acute sequelae of sars-cov-2 infection, and return to play: A report of the american college of cardiology solution set oversight committee[J]. J Am Coll Cardiol, 2022, 79(17):1717-1756.
[65] DAVIS HE, ASSAF GS, MCCORKELL L, et al.Characterizing long COVID in an international cohort: 7 months of symptoms and their impact[J]. EClinicalMedicine, 2021, 38:101019.
[66] GONZALEZ-ANDRADE F.Post-COVID-19 conditions in ecuadorian patients: An observational study[J]. Lancet Reg Health Am, 2022, 5:100088.
[67] MAZZA MG, DE LORENZO R, CONTE C, et al.Anxiety and depression in COVID-19 survivors: Role of inflammatory and clinical predictors[J]. Brain Behav Immun, 2020, 89:594-600.
[68] TOWNSEND L, DYER AH, JONES K, et al.Persistent fatigue following SARS-CoV-2 infection is common and independent of severity of initial infection[J]. PLoS One. 2020, 15(11):e0240784.
[69] LAM MH, WING YK, YU MW, et al.Mental morbidities and chronic fatigue in severe acute respiratory syndrome survivors: Long-term follow-up[J]. Arch Intern Med, 2009, 169(22):2142-2147.
[70] KOVARIK JJ, BILECK A, HAGN G, et al.A multi-omics based anti-inflammatory immune signature characterizes long COVID-19 syndrome[J]. iScience, 2023, 26(1):105717.
[71] HERRMAN H, PATEL V, KIELING C, et al.Time for united action on depression: A lancet-world psychiatric association commission[J]. Lancet, 2022, 399(10328):957-1022.
[72] LAKHAN R, AGRAWAL A, SHARMA M.Prevalence of Depression, Anxiety, and Stress during COVID-19 Pandemic[J]. J Neurosci Rural Pract, 2020, 11(4):519-525.
[73] DEMIRYUREK E, CEKIC D, ISSEVER K, et al.Depression and anxiety disorders in COVID-19 survivors: Role of inflammatory predictors[J]. Noro Psikiyatr Ars, 2022, 59(2):105-109.
[74] ZHU C, ZHANG T, LI Q, et al.Depression and Anxiety During the COVID-19 Pandemic: Epidemiology, Mechanism, and Treatment[J]. Neurosci Bull, 2023, 39(4):675-684.
[75] PAPPA S, NTELLA V, GIANNAKAS T, et al.Prevalence of depression, anxiety, and insomnia among healthcare workers during the COVID-19 pandemic: A systematic review and meta-analysis[J]. Brain Behav Immun, 2020, 88:901-907.
[76] KUBOTA T, KURODA N, SONE D.Neuropsychiatric aspects of long COVID: A comprehensive review[J]. Psychiatry Clin Neurosci, 2023, 77(2):84-93.
[77] ALMERIA M, CEJUDO JC, SOTOCA J, et al.Cognitive profile following COVID-19 infection: Clinical predictors leading to neuropsychological impairment[J]. Brain Behav Immun Health, 2020, 9:100163.
[78] MANUKYAN P, DEVIATERIKOVA A, VELICHKOVSKY BB, et al.The Impact of Mild COVID-19 on Executive Functioning and Mental Health Outcomes in Young Adults[J]. Healthcare (Basel). 2022,10(10):1891.
[79] CARONNA E, POZO-ROSICH P.Headache as a symptom of COVID-19: Narrative review of 1-year research[J]. Curr Pain Headache Rep, 2021, 25(11):73.
[80] GARCIA-AZORIN D, LAYOS-ROMERO A, PORTA-ETESSAM J, et al.Post-COVID-19 persistent headache: A multicentric 9-months follow-up study of 905 patients[J]. Cephalalgia, 2022, 42(8):804-809.
[81] CARONNA E, BALLVE A, LLAURADO A, et al.Headache: A striking prodromal and persistent symptom, predictive of COVID-19 clinical evolution[J]. Cephalalgia, 2020, 40(13):1410-1421.
[82] LUDWIG S, SCHELL A, BERKEMANN M, et al.Post-COVID-19 Impairment of the Senses of Smell, Taste, Hearing, and Balance[J]. Viruses, 2022, 14(5):849.
[83] TAN BKJ, HAN R, ZHAO JJ, et al.Prognosis and persistence of smell and taste dysfunction in patients with COVID-19: Meta-analysis with parametric cure modelling of recovery curves[J]. BMJ, 2022, 378: e069503.
[84] ROSA KYA, PADUA KLC, MALDANER VZ, et al.Musculoskeletal consequences from COVID-19 and the importance of pulmonary rehabilitation program[J]. Respiration, 2021, 100(10):1038-1040.
[85] KOWAL M, MORGIEL E, WINIARSKI S, et al.Effect of COVID-19 on musculoskeletal performance in gait and the timed-up and go test[J]. J Clin Med, 2023, 12(13):4184.
[86] KEKLICEK H, SELCUK H, KURT I, et al.Individuals with a COVID-19 history exhibit asymmetric gait patterns despite full recovery[J]. J Biomech, 2022, 137:111098.
[87] CHOUDHURY A, TARIQ R, JENA A, et al.Gastrointestinal manifestations of long COVID: A systematic review and meta-analysis[J]. Therap Adv Gastroenterol, 2022, 15:17562848221118403.
[88] SCHMULSON M, GHOSHAL UC, BARBARA G.Managing the inevitable surge of post-COVID-19 functional gastrointestinal disorders[J]. Am J Gastroenterol, 2021, 116(1):4-7.
[89] LIU Q, MAK JWY, SU Q, et al.Gut microbiota dynamics in a prospective cohort of patients with post-acute COVID-19 syndrome[J]. Gut, 2022, 71(3):544-552.
[90] CAI Q, HUANG D, YU H, et al.COVID-19: Abnormal liver function tests[J]. J Hepatol, 2020, 73(3):566-574.
[91] JOTHIMANI D, VENUGOPAL R, ABEDIN MF, et al.COVID-19 and the liver[J]. J Hepatol, 2020, 73(5):1231-1240.
[92] KOVALIC AJ, HUANG G, THULUVATH PJ, et al.Elevated liver biochemistries in hospitalized chinese patients with severe COVID-19: Systematic review and meta-analysis[J]. Hepatology, 2021, 73(4):1521-1530.
[93] LIAO X, LI D, MA Z, et al.12-month post-discharge liver function test abnormalities among patients with COVID-19: A single-center prospective cohort study[J]. Front Cell Infect Microbiol, 2022, 12:864933.
[94] CABALLERO-ALVARADO J, ZAVALETA CORVERA C, MERINO BACILIO B, et al.Post-COVID cholangiopathy: A narrative review[J]. Gastroenterol Hepatol, 2023, 46(6):474-482.
[95] CESAR MACHADO MC, FILHO RK, EL BACHA IAH, et al.Post-COVID-19 secondary sclerosing cholangitis: A rare but severe condition with no treatment besides liver transplantation[J]. Am J Case Rep, 2022, 23: e936250.
[96] URHAN E, KARACA Z, UNUVAR GK, et al.Investigation of pituitary functions after acute coronavirus disease 2019[J]. Endocr J, 2022, 69(6):649-658.
[97] OGUZ SH, YILDIZ BO.Endocrine disorders and COVID-19[J]. Annu Rev Med, 2023, 74:75-88.
[98] CLARKE SA, PHYLACTOU M, PATEL B, et al.Normal adrenal and thyroid function in patients who survive COVID-19 infection[J]. J Clin Endocrinol Metab, 2021, 106(8):2208-2220.
[99] LISCO G, DE TULLIO A, JIRILLO E, et al.Thyroid and COVID-19: A review on pathophysiological, clinical and organizational aspects[J]. J Endocrinol Invest, 2021, 44(9):1801-1814.
[100] LUI DTW, LEE CH, CHOW WS, et al.Role of non-thyroidal illness syndrome in predicting adverse outcomes in COVID-19 patients predominantly of mild-to-moderate severity[J]. Clin Endocrinol (Oxf), 2021, 95(3):469-477.
[101] TRIMBOLI P, CAPPELLI C, CROCE L, et al.COVID-19-associated subacute thyroiditis: Evidence-based data from a systematic review[J]. Front Endocrinol (Lausanne), 2021, 12:707726.
[102] RABAAN AA, SMAJLOVIC S, TOMBULOGLU H, et al.Sars-cov-2 infection and multi-organ system damage: A review[J]. Biomol Biomed, 2023, 23(1):37-52.
[103] MONTEFUSCO L, BEN NASR M, D'ADDIO F, et al. Acute and long-term disruption of glycometabolic control after sars-cov-2 infection[J]. Nat Metab, 2021, 3(6):774-785.
[104] LAURENZI A, CARETTO A, MOLINARI C, et al.No evidence of long-term disruption of glycometabolic control after sars-cov-2 infection[J]. J Clin Endocrinol Metab, 2022, 107(3): e1009-e1019.
[105] D'SOUZA D, EMPRINGHAM J, PECHLIVANOGLOU P, et al. Incidence of diabetes in children and adolescents during the COVID-19 pandemic: A systematic review and meta-analysis[J]. JAMA Netw Open, 2023, 6(6): e2321281.
[106] FERNANDEZ-DE-LAS-PENAS C, GUIJARRO C, TORRES-MACHO J, et al. Diabetes and the risk of long-term post-COVID symptoms[J]. Diabetes, 2021, 70(12):2917-2921.
[107] SUBRAMANIAN A, NIRANTHARAKUMAR K, HUGHES S, et al.Symptoms and risk factors for long COVID in non-hospitalized adults[J]. Nat Med, 2022, 28(8):1706-1714.
[108] XU E, XIE Y, AL-ALY Z.Risks and burdens of incident dyslipidaemia in long COVID: A cohort study[J]. Lancet Diabetes Endocrinol, 2023, 11(2):120-128.
[109] DEUEL JW, LAURIA E, LOVEY T, et al.Persistence, prevalence, and polymorphism of sequelae after COVID-19 in unvaccinated, young adults of the swiss armed forces: A longitudinal, cohort study (locomo)[J]. Lancet Infect Dis, 2022, 22(12178):1694-1702.
[110] FISHER M, NEUGARTEN J, BELLIN E, et al.Aki in hospitalized patients with and without COVID-19: A comparison study[J]. J Am Soc Nephrol, 2020, 31(9):2145-2157.
[111] HSU CM, GUPTA S, TIGHIOUART H, et al.Kidney recovery and death in critically ill patients with COVID-19-associated acute kidney injury treated with dialysis: The stop-COVID cohort study[J]. Am J Kidney Dis, 2022, 79(3):404-416 e401.
[112] NUGENT J, AKLILU A, YAMAMOTO Y, et al.Assessment of acute kidney injury and longitudinal kidney function after hospital discharge among patients with and without COVID-19[J]. JAMA Netw Open, 2021, 4(3): e211095.
[113] JEWELL PD, BRAMHAM K, GALLOWAY J, et al.COVID-19-related acute kidney injury; incidence, risk factors and outcomes in a large uk cohort[J]. BMC Nephrol, 2021, 22(1):359.
[114] CRETA M, SAGNELLI C, CELENTANO G, et al.Sars-cov-2 infection affects the lower urinary tract and male genital system: A systematic review[J]. J Med Virol, 2021, 93(5):3133-3142.
[115] ZACHARIOU A, SAPOUNA V, KALTSAS A, et al.Evaluation of overactive bladder symptoms in patients recovering from post-acute COVID-19 syndrome[J]. J Multidiscip Healthc, 2022, 15:2447-2452.
[116] SELVI I, DONMEZ MI, ZIYLAN O, et al.Urodynamically proven lower urinary tract dysfunction in children after COVID-19: A case series[J]. Low Urin Tract Symptoms, 2022, 14(4):301-304.
[117] KRESCH E, ACHUA J, SALTZMAN R, et al.COVID-19 endothelial dysfunction can cause erectile dysfunction: Histopathological, immunohistochemical, and ultrastructural study of the human penis[J]. World J Mens Health, 2021, 39(3):466-469.
[118] KAYNAR M, GOMES ALQ, SOKOLAKIS I, et al.Tip of the iceberg: Erectile dysfunction and COVID-19[J]. Int J Impot Res, 2022, 34(2):152-157.
[119] SUN X, LYU J.A short review of male genito-urinary lesions caused by coronavirus disease 2019[J]. Curr Urol, 2022, 16(2):63-64.
[120] HAJIZADEH MALEKI B, TARTIBIAN B.COVID-19 and male reproductive function: A prospective, longitudinal cohort study[J]. Reproduction, 2021, 161(3):319-331.
[121] SHARP GC, FRASER A, SAWYER G, et al.The COVID-19 pandemic and the menstrual cycle: Research gaps and opportunities[J]. Int J Epidemiol, 2022, 51(3):691-700.
[122] LI K, CHEN G, HOU H, et al.Analysis of sex hormones and menstruation in COVID-19 women of child-bearing age[J]. Reprod Biomed Online, 2021, 42(1):260-267.
[123] URSINI F, CIAFFI J, MANCARELLA L, et al.Fibromyalgia: A new facet of the post-COVID-19 syndrome spectrum? Results from a web-based survey[J]. Rmd Open, 2021, 7(3): e001735.
[124] KARAARSLAN F, GUNERI FD, KARDES S.Long COVID: Rheumatologic/musculoskeletal symptoms in hospitalized COVID-19 survivors at 3 and 6 months[J]. Clin Rheumatol, 2022, 41(1):289-296.
[125] CIAFFI J, MELICONI R, RUSCITTI P, et al.Rheumatic manifestations of COVID-19: a systematic review and meta-analysis[J]. BMC Rheumatol, 2020, 4:65
[126] DERKSEN V, KISSEL T, LAMERS-KARNEBEEK FBG, et al.Onset of rheumatoid arthritis after COVID-19: Coincidence or connected?[J]. Ann Rheum Dis, 2021, 80(8):1096-1098.
[127] MUKARRAM MS, ISHAQ GHAURI M, SETHAR S, et al.COVID-19: An emerging culprit of inflammatory arthritis[J]. Case Rep Rheumatol, 2021, 2021:6610340.
[128] URSINI F, RUSCITTI P, D'ANGELO S, et al. Broad clinical spectrum of sars-cov-2-associated inflammatory joint disease in adults: A report of 35 cases from the COVID-19 & autoimmune systemic disease italian study group[J]. Ann Rheum Dis, 2021, 80(11):1498-1501.
[129] TAHA SI, SAMAAN SF, IBRAHIM RA, et al.Post-COVID-19 arthritis: Is it hyperinflammation or autoimmunity?[J]. Eur Cytokine Netw, 2021, 32(4):83-88.
[130] AKEL A, ALMANASYEH B, ABO KOBAA A, et al.A cross-sectional study of fibromyalgia and post-acute COVID-19 syndrome (pacs): Could there be a relationship?[J]. Cureus, 2023, 15(7): e42663.
[131] PINTO AA, CARROLL LS, NAR V, et al.CNS inflammatory vasculopathy with antimyelin oligodendrocyte glycoprotein antibodies in COVID-19[J]. Neurol Neuroimmunol Neuroinflamm, 2020, 7(5): e813.
[132] FUJII H, TSUJI T, YUBA T, et al.High levels of anti-ssa/ro antibodies in COVID-19 patients with severe respiratory failure: A case-based review: High levels of anti-ssa/ro antibodies in COVID-19[J]. Clin Rheumatol, 2020, 39(11):3171-3175.
[133] VENKATAKRISHNAN AJ, KAYAL N, ANAND P, et al.Benchmarking evolutionary tinkering underlying human-viral molecular mimicry shows multiple host pulmonary-arterial peptides mimicked by sars-cov-2[J]. Cell Death Discov, 2020, 6(1):96.
[134] SAPKOTA HR, NUNE A.Long COVID from rheumatology perspective - a narrative review[J]. Clin Rheumatol, 2022, 41(2):337-348.
[135] LIU Y, SAWALHA AH, LU Q.COVID-19 and autoimmune diseases[J]. Curr Opin Rheumatol, 2021, 33(2):155-162.
[136] NOVELLI L, MOTTA F, DE SANTIS M, et al.The janus of chronic inflammatory and autoimmune diseases onset during COVID-19 - a systematic review of the literature[J]. J Autoimmun, 2021, 117:102592.
[137] ANTONELLI M, PUJOL JC, SPECTOR TD, et al.Risk of long COVID associated with delta versus omicron variants of sars-cov-2[J]. Lancet, 2022, 399(10343):2263-2264.
[138] CROOK H, RAZA S, NOWELL J, et al.Long COVID-mechanisms, risk factors, and management[J]. BMJ, 2021, 374: n1648.
[139] GEBHARD CE, SÜTSCH C, GEBERT P, et al. Impact of sex and gender on post-COVID-19 syndrome, Switzerland, 2020[J]. Euro Surveill, 2024, 29(2):2300200.
[140] WANG S, QUAN L, CHAVARRO JE, et al.Associations of depression, anxiety, worry, perceived stress, and loneliness prior to infection with risk of post-COVID-19 conditions[J]. JAMA Psychiatry, 2022, 79(11):1081-1091.
[141] PAZUKHINA E, ANDREEVA M, SPIRIDONOVA E, et al.Prevalence and risk factors of post-COVID-19 condition in adults and children at 6 and 12 months after hospital discharge: A prospective, cohort study in moscow (stopCOVID)[J]. BMC Med, 2022, 20(1):244.
[142] SUDRE CH, MURRAY B, VARSAVSKY T, et al.Attributes and predictors of long COVID[J]. Nat Med, 2021, 27(4):626-631.
[143] THOMPSON EJ, WILLIAMS DM, WALKER AJ, et al.Long COVID burden and risk factors in 10 uk longitudinal studies and electronic health records[J]. Nat Commun, 2022, 13(1):3528.
[144] BAI F, TOMASONI D, FALCINELLA C, et al. Female gender is associated with long COVID syndrome: A prospective cohort study[J]. Clin Microbiol Infect, 2022, 28(4): 611.e9-611.e16.
[145] OSMANOV IM, SPIRIDONOVA E, BOBKOVA P, et al.Risk factors for post-COVID-19 condition in previously hospitalised children using the isaric global follow-up protocol: A prospective cohort study[J]. Eur Respir J, 2022, 59(2): 2101341.
[146] ANTONELLI M, PENFOLD RS, CANAS LDS, et al.SARS-CoV-2 infection following booster vaccination: Illness and symptom profile in a prospective, observational community-based case-control study[J]. J Infect. 2023, 87(6):506-515.
[147] DAVIS HE, MCCORKELL L, VOGEL JM, et al.Author correction: Long COVID: Major findings, mechanisms and recommendations[J]. Nat Rev Microbiol, 2023, 21(6):408.
[148] AYOUBKHANI D, BOSWORTH ML, KING S, et al. Risk of Long COVID in People Infected With Severe Acute Respiratory Syndrome Coronavirus 2 After 2 Doses of a Coronavirus Disease2019 Vaccine: Community-Based, Matched Cohort Study[J]. Open Forum Infect Dis, 2022, 9(9):ofac464.
[149] MA Y, DENG J, LIU Q, et al.Long-term consequences of asymptomatic sars-cov-2 infection: A systematic review and meta-analysis[J]. Int J Environ Res Public Health, 2023, 20(2): 1613.
[150] DAVIS HE, MCCORKELL L, VOGEL JM, et al.Long COVID: Major findings, mechanisms and recommendations[J]. Nat Rev Microbiol, 2023, 21(3):133-146.
[151] XIE Y, CHOI T, AL-ALY Z.Association of treatment with nirmatrelvir and the risk of post-COVID-19 condition[J]. JAMA Intern Med, 2023, 183(6):554-564.
[152] GRIST JT, COLLIER GJ, WALTERS H, et al.Lung abnormalities detected with hyperpolarized (129)xe mri in patients with long COVID[J]. Radiology, 2022, 305(3):709-717.
[153] ROCA-FERNANDEZ A, WAMIL M, TELFORD A, et al.Cardiac abnormalities in long COVID 1-year post-sars-cov-2 infection[J]. Open Heart, 2023, 10(1): e002241.
[154] FERNANDEZ-DE-LAS-PENAS C, PALACIOS-CENA D, GOMEZ-MAYORDOMO V, et al. Defining post-COVID symptoms (post-acute COVID, long COVID, persistent post-COVID): An integrative classification[J]. Int J Environ Res Public Health, 2021, 18(5): 2621.
[155] RAGHU G, WILSON KC.COVID-19 interstitial pneumonia: Monitoring the clinical course in survivors[J]. Lancet Respir Med, 2020, 8(9):839-842.
[156] RAI DK, SHARMA P, KARMAKAR S, et al.Approach to post COVID-19 persistent cough: A narrative review[J]. Lung India, 2023, 40(2):149-154.
[157] KELLE S, BUCCIARELLI-DUCCI C, JUDD RM, et al.Society for cardiovascular magnetic resonance (scmr) recommended cmr protocols for scanning patients with active or convalescent phase COVID-19 infection[J]. J Cardiovasc Magn Reson, 2020, 22(1):61.
[158] KOCIOL RD, COOPER LT, FANG JC, et al.Recognition and initial management of fulminant myocarditis: A scientific statement from the american heart association[J]. Circulation, 2020, 141(6): e69-e92.
[159] DOUAUD G, LEE S, ALFARO-ALMAGRO F, et al.Sars-cov-2 is associated with changes in brain structure in uk biobank[J]. Nature, 2022, 604(7907):697-707.
[160] ORTELLI P, FERRAZZOLI D, SEBASTIANELLI L, et al.Neuropsychological and neurophysiological correlates of fatigue in post-acute patients with neurological manifestations of COVID-19: Insights into a challenging symptom[J]. J Neurol Sci, 2021, 420:117271.
[161] BOUTELEUX B, HENROT P, ERNST R, et al.Respiratory rehabilitation for COVID-19 related persistent dyspnoea: A one-year experience[J]. Respir Med, 2021, 189:106648.
[162] MYALL KJ, MUKHERJEE B, CASTANHEIRA AM, et al.Persistent post-COVID-19 interstitial lung disease. An observational study of corticosteroid treatment[J]. Ann Am Thorac Soc, 2021, 18(5):799-806.
[163] GOEL N, GOYAL N, NAGARAJA R, et al.Systemic corticosteroids for management of‘long-COVID': An evaluation after 3 months of treatment[J]. Monaldi Arch Chest Dis, 2021, 92(2):10.
[164] DHOORIA S, CHAUDHARY S, SEHGAL IS, et al.High-dose versus low-dose prednisolone in symptomatic patients with post-COVID-19 diffuse parenchymal lung abnormalities: An open-label, randomised trial (the coldster trial)[J]. Eur Respir J, 2022, 59(2): 2102930.
[165] MYALL KJ, MUKHERJEE B, CASTANHEIRA AM, et al.Persistent Post-COVID-19 Interstitial Lung Disease. An Observational Study of Corticosteroid Treatment[J]. Ann Am Thorac Soc. 2021, 18(5):799-806.
[166] FUNKE-CHAMBOUR M, BRIDEVAUX PO, CLARENBACH CF, et al.Swiss recommendations for the follow-up and treatment of pulmonary long COVID[J]. Respiration, 2021, 100(8):826-841.
[167] HIRAWAT R, JAIN N, ASLAM SAIFI M, et al.Lung fibrosis: Post-COVID-19 complications and evidences[J]. Int Immunopharmacol, 2023, 116:109418.
[168] DHOORIA S, MATURU VN, TALWAR D, et al.A multicenter survey study of antifibrotic use for symptomatic patients with post-COVID-19 interstitial lung abnormalities[J]. Lung India, 2022, 39(3):254-260.
[169] KERGET B, CIL G, ARAZ O, et al.Comparison of two antifibrotic treatments for lung fibrosis in post-COVID-19 syndrome: A randomized, prospective study[J]. Med Clin (Engl Ed), 2023, 160(12):525-530.
[170] CHOUDHARY R, KUMAR A, ALI O, et al.Effectiveness and safety of pirfenidone and nintedanib for pulmonary fibrosis in COVID-19 induced severe pneumonia: An interventional study[J]. Cureus, 2022, 14(9): e29435.
[171] 中国医师协会心血管内科医师分会. 新型冠状病毒感染与心血管疾病诊疗中国专家共识(2023)[J]. 中华心血管病杂志(网络版), 2023, 6(1):1-22.
[172] KUUT TA, MULLER F, CSORBA I, et al.Efficacy of cognitive-behavioral therapy targeting severe fatigue following coronavirus disease 2019: Results of a randomized controlled trial[J]. Clin Infect Dis, 2023, 77(5):687-695.
[173] VINK M, VINK-NIESE A.The draft report by the institute for quality and efficiency in healthcare does not provide any evidence that graded exercise therapy and cognitive behavioral therapy are safe and effective treatments for myalgic encephalomyelitis/chronic fatigue syndrome[J]. Diseases, 2023, 11(1):11.
[174] FENG BW, RONG PJ. Acupoint stimulation for long COVID: A promising intervention[J]. World J Acupunct Moxibustion, 2023.Online ahead of print.
[175] BARLETTA MA, MARINO G, SPAGNOLO B, et al.Coenzyme q10 + alpha lipoic acid for chronic COVID syndrome[J]. Clin Exp Med, 2023, 23(3):667-678.
[176] SISÓ-ALMIRALL A, BRITO-ZERÓN P, CONANGLA FERRÍN L, et al. Long COVID-19: Proposed Primary Care Clinical Guidelines for Diagnosis and Disease Management[J]. Int J Environ Res Public Health, 2021, 18(8):4350.
[177] DONELLI D, ANTONELLI M, VALUSSI M.Olfactory training with essential oils for patients with post-COVID-19 smell dysfunction: A case series[J]. Eur J Integr Med, 2023, 60:102253.
[178] RODRIGUEZ LUGO DA, CORONADO TOVAR JJ, SOLANO VILLAMARIN GA, et al.primary biliary cholangitis. Part 2. State of the art, diagnosis, associated diseases, treatment and prognosis[J]. Rev Gastroenterol Peru, 2018, 38(1):64-71.
[179] DURAZO FA, KRISTBAUM K, MILLER J, et al.De novo autoimmune hepatitis after COVID-19 infection in an unvaccinated patient[J]. Case Reports Hepatol, 2022, 2022:8409269.
[180] BRAMANTE CT, BUSE JB, LIEBOVITZ DM, et al.Outpatient treatment of COVID-19 and incidence of post